Delstrigo® accepted by SMC for HIV-1 in adults without past or present evidence of resistance to the NNRTI class, lamivudine, or tenofovir

It offers an additional treatment choice of NNRTI-based single-tablet regimen for this indication.

Join OnMedica and benefit from:

  • Bitesize CPD and easy to digest content, free for UK-based GPs and specialist doctors
  • High-quality, evidence-based content developed by expert editors and clinicians
  • Articles, quizzes, videos, visual summaries and more
  • Regulatory alerts and round-up of medical journals
  • New content added daily, so you know you’re always up to date
Register

Existing members Sign in